METACARE Discloses Corporate Governance Report: Capital Reduction Eliminates Deficit and Lays Foundation for Dividends, but Governance Deficiencies Persist


  • Massive capital reduction executed: Shares reduced from 171,777,364 to 17,177,736 (1/10) to offset accumulated deficits and improve capital efficiency. No dilution of per-share value; considered a proactive step to normalize financial structure and lay groundwork for future shareholder returns such as dividends.
  • Lack of shareholder return policy and no dividends: No dividends paid in the last three fiscal years, no formal dividend policy or mid- to long-term shareholder return plan, resulting in low dividend predictability. The company plans to establish a policy after improving profitability, but no specific timeline has been set.
  • Non-compliance with 12 out of 15 core governance indicators: Fails to meet best practices in areas such as 4-week advance notice of shareholder meetings, dividend policy disclosure, CEO succession planning, enterprise risk management, and independence of internal audit. Particularly, the practice of convening shareholder meetings only 2 weeks in advance and absence of internal control policies may undermine transparency and require improvement.
  • Expansion of related-party transactions and potential conflicts of interest: During the period, equity acquisitions and loans to related parties totaled KRW 45.8 billion. No comprehensive board approval process exists for transactions with the largest shareholder and affiliates. Strengthened prior review and disclosure to prevent conflicts of interest are needed.
  • Issuance of KRW 10 billion convertible bonds for investment in other companies: In September 2025, the 17th series private CB of KRW 10 billion was issued to fund acquisition of securities in other corporations. Potential conversion price adjustments and dilution risk for existing shareholders remain.
  • [AI Comprehensive Analysis]METACARE has eliminated its deficit through a massive capital reduction and secured resources for potential dividends, but significant governance deficiencies persist, making shareholder trust recovery a challenge. If the company concretizes a dividend policy, strengthens board independence, and establishes an internal control system, it could positively impact the stock price; however, failure to improve in the short term could pose investment risks.

KOSPI Filing Information


  • Filing: Corporate Governance Report Disclosure
  • Company: METACARE (118000)
  • Submission: METACARE Co., Ltd.
  • Receipt: 05-29-2026
  • Under KRX KOSPI Market Division